Clinical Trial Update: Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase II study evaluating MEDI4736 (durvalumab) with tremelimumab in combination for recurrent/metastatic squamous cell carcinoma of the head and neck has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• MEDI4736 (Durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck | Phase 2 | Status: COMPLETED | Results posted: 2018-06-19